Brazil Health Group Dasa Profit Jumps 79%

Dasa, a Brazilian medical testing and hospital group, reported a significant jump in profit from continuing operations in the third quarter of 2026. Profit from ongoing businesses increased by 78.7% to R$173 million (approximately US$31 million). However, overall sales declined primarily due to the company's restructuring efforts.

The company's shares are traded on the B3, the S&P São Paulo stock exchange. For U.S. readers, these figures illustrate how a Brazilian health company is striving to increase earnings while reducing debt. Dasa's third-quarter 2026 results were published on Thursday, November 5, 2026. Profit from continuing operations, which includes the businesses still under Dasa's control, reached R$173 million (about US$31 million at an exchange rate of R$5.50 per US dollar).

Gross revenue amounted to R$2.6 billion (approximately US$470 million), a 9% decrease compared to the previous year. The decline is attributed to the deconsolidation of Ímpar, Dasa's former hospital unit, and the sale of other assets in 2025. On a like-for-like basis, which only counts the businesses Dasa currently owns, revenue grew by 8%.

The diagnostics arm, responsible for running laboratories and testing centers across Brazil, generated R$2.4 billion (about US$436 million) in gross revenue, an increase of 8%. Essentially, Dasa no longer includes every hospital it once owned in its calculations. Ímpar now operates within the Rede América joint venture with health insurer Amil, so Dasa only records its share of that network's profit instead of all sales.

The company's hospitals and oncology business in the Northeast reported revenue of R$231 million (about US$42 million), an 7% increase. Dasa's net debt, which is the amount owed after accounting for cash, has also decreased compared to the previous year. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were R$640 million (approximately US$116 million), a margin of 26.6%.

This figure exceeded the expected R$585 million (about US$106 million) according to consensus data from LSEG, a financial data provider. EBITDA was still 7.4% lower than a year earlier, partly because Rede América contributed less. Without that effect, Dasa says EBITDA was R$617 million (about US$112 million), a 4.7% increase on the current scope.

Free cash flow, the cash remaining after operating expenses and investments, was R$369 million (about US$67 million), a 11.1% decrease from R$415 million (approximately US$75 million). Net financial debt ended September at R$5.4 billion (about US$980 million), a 18% reduction or 2.76 times current-scope EBITDA. Chief executive Rafael Lucchesi stated that the company continues to focus on growth while maintaining profitability, improving productivity, and strengthening cash generation.

He added that growth is still occurring at a higher comparison base. If you own Brazilian stocks through a U.S. fund, Dasa demonstrates lower debt even as the business is smaller, though free cash flow fell by 11.1%. All figures are converted to approximately R$5.50 per US dollar, the closing exchange rate on November 5, 2026 (source: RT, a market data provider).

The 1.9 percentage-point fall in gross margin to 31.9% is attributed mainly to accounting reclassifications of costs and expenses. It is unclear if this trend will continue. We have not seen any dividend decisions or new debt targets. The share-price reaction on the first trading day after the release is not covered in this report. For further information on Brazil news in English, visit The Rio Times daily.